Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences (NASDAQ: ENVB) is a clinical-stage biotechnology company developing non-hallucinogenic derivatives of psychedelic compounds for neuropsychiatric disorders. Headquartered in Cambridge, Massachusetts, the company advances drug candidates through preclinical studies and toward FDA regulatory submissions.
News coverage for Enveric Biosciences typically centers on clinical development milestones and regulatory interactions. Updates on the company's lead candidate EB-003 and the EVM301 and EVM401 drug series provide insight into pipeline progression. Preclinical study results, IND submission timelines, and FDA feedback represent key developments that affect the company's trajectory.
Intellectual property announcements form another significant category of Enveric news. Patent issuances and notices of allowance for the company's synthetic psychedelic derivatives indicate the strength of its proprietary portfolio. For biotechnology investors, patent protection directly affects potential market exclusivity and commercial viability.
As a development-stage company without product revenue, financing activities frequently appear in Enveric's news flow. Warrant exercises, capital raises, and stock structure changes such as reverse splits provide transparency into how the company funds ongoing research operations. These announcements help investors understand share dilution and cash runway.
Scientific publications in peer-reviewed journals demonstrate research progress and validate the company's approach to neuropsychiatric drug development. Manufacturing milestone achievements signal advancement toward clinical-grade production capabilities needed for human trials.
Follow Enveric Biosciences news to track drug development progress, regulatory milestones, and financing activities that shape this clinical-stage biotechnology company's path toward potential commercialization.
Enveric Biosciences (NASDAQ: ENVB) said it retained Fish and Richardson to defend U.S. Patent No. 12,138,276 (the ‘276 patent) after a Post‑Grant Review petition was filed by Gilgamesh Pharmaceuticals on claims that appear relevant to Bretisilocin (GM‑2505), which AbbVie agreed to acquire on August 25, 2025 in a definitive transaction valued at up to $1.2 billion. The ‘276 family includes one issued U.S. patent, additional pending U.S. and international applications, and is separate from Enveric’s EB‑003 patent families.
Enveric reported an intellectual property portfolio of 26 issued U.S. patents and 60 pending national and international applications, multiple programs advancing toward clinical development, and out‑license agreements with potential aggregate milestones of up to $205 million plus royalties.
Enveric Biosciences (NASDAQ: ENVB) announced on October 14, 2025 that its Board authorized the Capital Markets Committee to explore and negotiate non-binding term sheets for potential Digital Asset Treasury (DAT) strategy opportunities.
Any DAT opportunities would require further review and approval by the full Board. The company said this initiative is intended to enhance shareholder value and support long-term growth while it remains committed to advancing its core biotechnology programs. The company will provide updates as developments occur.
Enveric Biosciences (NASDAQ: ENVB) has achieved significant chemistry, manufacturing, and controls (CMC) milestones for its lead candidate EB-003, advancing towards first-in-human clinical trials. The company has successfully: produced a pharmaceutically compatible salt form, developed a scalable synthetic route, and manufactured a 1-kilogram batch of EB-003.
EB-003 is a novel small molecule with dual agonism at 5-HT1B and 5-HT2A receptors, targeting neuropsychiatric conditions. These manufacturing achievements are crucial for supporting upcoming Investigational New Drug (IND) application activities, including GLP toxicology studies and drug product formulation work.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on neuroplastogenic small molecules, has announced the closing of previously announced warrant exercises, generating $2.2 million in gross proceeds. The transaction involved the exercise of series A and B warrants at a reduced price of $0.915 per share, down from the original $3.00 per share.
In exchange for the immediate cash exercise, Enveric issued new unregistered warrants: Series C warrants for up to 2,424,998 shares (5-year term) and Series D warrants for up to 2,424,998 shares (18-month term), both with a $0.915 exercise price. The company plans to use proceeds for product development, working capital, and general corporate purposes.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on neuroplastogenic small molecules, has announced warrant exercises that will generate $2.2 million in gross proceeds. The company secured agreements for the immediate exercise of series A and B warrants totaling 2,424,998 shares at a reduced price of $0.915 per share, down from the original $3.00 exercise price.
In exchange for the immediate cash exercise, Enveric will issue new unregistered series C and D warrants, each allowing the purchase of up to 2,424,998 shares at $0.915 per share. The series C warrants will have a 5-year term, while series D warrants will expire in 18 months. The company plans to use the proceeds for product development, working capital, and general corporate purposes.
Enveric Biosciences (NASDAQ: ENVB) announced the publication of two significant peer-reviewed research papers showcasing innovative bioproduction methods for neuropsychiatric drug discovery. The first paper in ACS Chemical Biology details the creation of 279 tryptamine derivatives, including 17 novel compounds showing interaction with melatonin and serotonin receptors. The second paper in BioDesign Research presents the first-ever bioproduction method for MDMA and related compounds using engineered yeast.
The company's lead candidate EB-003, manufactured through traditional synthetic chemistry, represents a novel class of neuroplastogens targeting both 5-HT₂A and 5-HT₁B receptors. Enveric plans to submit an Investigational New Drug (IND) application with first-in-human studies expected in 2026.
Enveric Biosciences (NASDAQ: ENVB) has received FDA response regarding its pre-IND Type B meeting request for EB-003, its lead neuroplastogenic program. The FDA recommended that Enveric proceed directly to submitting its Investigational New Drug (IND) application, suggesting the company's development strategy is sufficiently advanced.
The company plans to file the IND application for EB-003 in early 2026. EB-003 is designed as a dual-acting compound targeting depression and anxiety through durable neuroplastic changes without hallucinogenic effects. Enveric's intellectual property portfolio includes 26 issued U.S. patents and 60 pending national and international applications.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on neuroplastogenic small molecules, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Joseph Tucker, Ph.D., will deliver a virtual presentation on September 8, 2025, at 7:00 AM ET.
The presentation will highlight the company's pipeline of therapeutics for depression, anxiety, and addiction disorders, featuring their lead candidate EB-003. This compound is designed to provide neuroplastogenic benefits while minimizing hallucinatory effects, with a dual-targeting mechanism showing partial agonism at 5-HT₂A receptor and agonism at 5-HT₁B receptor. Dr. Tucker will also conduct one-on-one meetings with investors and potential partners.
Enveric Biosciences (NASDAQ: ENVB) has announced the relocation of its corporate headquarters to Cambridge, Massachusetts, positioning itself within one of the world's premier biotech hubs. The strategic move aims to leverage the Greater Boston area's scientific and financial ecosystem as the company prepares to advance its lead molecule, EB-003, into first-in-human clinical trials in 2026.
EB-003, representing a novel class of neuroplastogens, is designed to treat neuropsychiatric conditions through dual engagement of 5-HT₂A and 5-HT₁B receptors while minimizing hallucinatory effects. The company plans to submit an Investigational New Drug (IND) application, supported by encouraging preclinical data.
Enveric Biosciences (NASDAQ: ENVB) has successfully completed 7-day Dose Range Finding (DRF) toxicology studies for its lead drug candidate EB-003, a first-in-class neuroplastogen targeting depression, PTSD, and other neuropsychiatric disorders. The studies, conducted in two preclinical species, established the Maximum Tolerated Dose (MTD) and confirmed oral bioavailability with dose-dependent plasma concentration increases.
The results demonstrated CNS-related effects and brain penetration, supporting the compound's intended therapeutic use. EB-003 selectively engages serotonin 5-HT2A and 5-HT1B receptors to promote neural circuit remodeling without inducing hallucinations, potentially enabling outpatient administration for chronic conditions.
FAQ
What is the current stock price of Enveric Biosciences (ENVB)?
What is the market cap of Enveric Biosciences (ENVB)?
